A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

About the study

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.

Study point of contact

Deanna Franklin
[email protected]
Carolyn Hoppe, MD
[email protected]


8 United States sites

1 Lebanon site


> 12 Years


Phase 3

Study type



12 Years -







participation requirements

Participant has an index VOC. The index VOC is any VOC that required admission to a healthcare facility and treatment with parenteral pain medication. An admission for the index VOC includes:

A hospital admission, or
An admission to an emergency room, observation unit, or infusion center for ≥ 12 hours, or
2 visits to an emergency room, observation unit, or infusion center over a 72-hour period

for an acute episode of pain with no other cause other than a vaso- occlusive event that includes the following:

Uncomplicated VOC,
Acute chest syndrome (ACS),
Acute hepatic sequestration,
Acute splenic sequestration, or
Participant has a confirmed diagnosis of SCD (any genotype). Documentation of SCD genotype is required and may be based on documented history of laboratory testing or confirmed by laboratory testing at Baseline.
Participant is male or female, ≥ 12 years of age at the time of informed consent.

Participant has experienced between 2 and 10 VOCs within the 12 months prior to Screening as determined by documented medical history. The index VOC is not to be considered as one of the 2 to 10 events. A prior VOC is defined as an acute episode of pain that:

Has no medically determined cause other than a vaso-occlusive event, and
Results in a visit to a healthcare facility (hospital, emergency department, urgent care center, outpatient clinic, or infusion center) or results in a remote contact with a healthcare provider; and
Requires parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics.
Participants receiving erythropoiesis-stimulating agents (ESA, e.g., erythropoietin [EPO]) must be on a stable dose for at least 90 days prior to Screening and expected to continue with the stabilized regimen throughout the course of the study.
Participants receiving hydroxyurea (HU), L-glutamine, or voxelotor (Oxbryta®) must be on a stable dose for at least 30 days prior to Screening and expected to continue with the stabilized regimen throughout the course of the study.

participation restrictions

Participant is receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion).
Participant is taking or has received crizanlizumab (ADAKVEO®) within 90 days prior to Screening.
Participant weighs > 133 kg (292 lbs.).

Other protocol-defined Inclusion/Exclusion may apply.


  • Mobile, Alabama, United States, University of South Alabama Children's and Women's Hospital, 36604 [Not yet recruiting]
  • Little Rock, Arkansas, United States, Arkansas Children's Hospital, 72202 [Recruiting]
  • Atlanta, Georgia, United States, Children's Healthcare of Atlanta at Scottish Rite Hospital, 30342 [Not yet recruiting]
  • Chicago, Illinois, United States, University of Illinois at Chicago, 60607 [Not yet recruiting]
  • Ann Arbor, Michigan, United States, University of Michigan, 48109 [Recruiting]
  • Bronx, New York, United States, Jacobi Medical Center, 10461 [Recruiting]
  • Durham, North Carolina, United States, Duke University Medical Center, 27710 [Not yet recruiting]
  • Memphis, Tennessee, United States, St Jude Children's Research Hospital, 38105 [Not yet recruiting]
  • Tripoli, Lebanon, Nini Hospital [Recruiting]
Last updated 2022-03-14